Pharmaceutical care recommendations for antiviral treatments in children with coronavirus disease 2019

World J Pediatr. 2020 Jun;16(3):271-274. doi: 10.1007/s12519-020-00353-5. Epub 2020 Mar 12.
No abstract available

Publication types

  • Review

MeSH terms

  • Adolescent
  • Age Factors
  • Antiviral Agents / administration & dosage*
  • Antiviral Agents / pharmacology
  • COVID-19
  • Child
  • Child, Preschool
  • China
  • Chloroquine / administration & dosage
  • Chloroquine / analogs & derivatives
  • Coronavirus Infections / diagnosis
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / epidemiology
  • Female
  • Humans
  • Indoles / administration & dosage
  • Infant
  • Infant, Newborn
  • Interferon-alpha / administration & dosage
  • Lopinavir / administration & dosage
  • Male
  • Pandemics
  • Pharmaceutical Services*
  • Pneumonia, Viral / diagnosis
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / epidemiology
  • Practice Guidelines as Topic*
  • Prognosis
  • Ribavirin / administration & dosage
  • Risk Assessment
  • Severe Acute Respiratory Syndrome / diagnosis
  • Severe Acute Respiratory Syndrome / drug therapy*
  • Severe Acute Respiratory Syndrome / epidemiology
  • Treatment Outcome

Substances

  • Antiviral Agents
  • Indoles
  • Interferon-alpha
  • Lopinavir
  • Ribavirin
  • chloroquine diphosphate
  • Chloroquine
  • umifenovir